• These Professionals Are Creating Our Outsourcing Future

    While asking executives their views on the future of outsourcing drug development and manufacturing, I arrived at an epiphany of sorts: They are the future of biopharma outsourcing.

  • Why CDMO Brand Positioning Data Is Of Value To Sponsors

    Understanding the competitive outsourced manufacturing landscape is essential for CDMOs, and can add valuable insight on lesser-known companies for outsourcers.

  • Message To CROs: Keep That Pandemic Tool Belt Handy

    During the last year, despite countless obstacles and dangers, the pharma industry managed to remain steadfast and get to where we are today – hopefully with COVID-19 in the rear-view mirror. Let’s take a closer look at the numbers.

  • An All-Canada COVID-19 Vaccine Solution

    The story of how Providence Therapeutics, a Calgary, Ontario-based, emerging mRNA biopharma, came to achieve such notoriety is an interesting one that includes a pivot from its core therapeutic focus, the hiring of an American as company president, and the creation of a CDMO.

  • Should Your CDMO Become A 503B?

    A reader pulled me down an Alice-In-Wonderland rabbit hole. I’m glad she did, though. If you read the headline above and thought, “What exactly is a 503B?” you’ll be glad, too.  

  • Insights On How Outsourcing Decisions Are Made

    How does your company’s approach to making outsourcing decisions compare with others in the industry? Data from ISR’s CDMO outsourcing models report highlights common practices that, when adopted, may improve outsourcing outcomes from drug innovators’ perspectives.

  • Position Your CDMO For Competitive Advantage

    “Outsourcing is really about positioning your CDMO to your competitive advantage,” says Lisa Wyman, SVP technical operations and quality at Acceleron Pharma.

  • CMOs Continue To Exceed Sponsor Expectations

    ISR explains how the CMO Leadership Awards and the corresponding market research data can be used to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.

  • The Challenges Provided Us A Deeper Meaning

    The past year of travel and other restrictions have skewed the biopharma outsourcer’s mantra of “trust but verify” to a heavier weight on the first of those two components. For some, this was easier to deal with than others.

  • Drug Delivery Systems’ Increasing Role In Patient Outcomes: What’s Next?

    The role of DDS providers to pharma evolved from transactional suppliers to innovation partners, and the-yet-to-be-met promises of IoMT place them more and more at the center of attention.